Qiagen N.V. (NYSE:QGEN) Given Average Rating of "Hold" by Brokerages
Twelve brokerages have given Qiagen N.V. (NYSE:QGEN) an average "Hold" rating, with a mean 12-month price target of $55.20. The company recently beat earnings and revenue estimates for its last quarter, posting $0.62 EPS on $540.4 million in revenue, and has provided positive guidance for fiscal year 2026. Institutional investors hold approximately 70% of the stock.
Qiagen (QGEN) upgraded to buy by Deutsche Bank after 30% decline
Deutsche Bank has upgraded Qiagen (QGEN) stock from hold to buy following a significant 30% decline in its share price. The upgrade reflects an improved risk/reward profile for the diagnostic test maker. Analyst Mark Massaro noted that while growth concerns persist, the valuation has become more attractive.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, as informed by the AFM on April 2, 2026. The notification details transactions and holdings by Bank of America Corporation, showing a total capital interest and voting rights of 3.01% in QIAGEN N.V. The reported transactions occurred on March 30, 2026, and include direct and indirect holdings through various entities.
Bank of America Discloses 3.01% Voting Stake in Qiagen
Bank of America Corporation and its affiliates have disclosed a 3.01% capital and voting interest in Qiagen, a Netherlands-based life sciences company. This stake comprises both actual shares and derivatives like swaps and call options, highlighting Bank of America's position as a significant institutional shareholder. The disclosure provides increased transparency regarding Qiagen's ownership structure and potential influences on its shareholder dynamics.
QGEN Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for Qiagen NV (QGEN), indicating a "Sell" consensus based on various technical indicators as of April 6, 2026. Key metrics like MACD and moving averages suggest a bearish trend, with the stock trading below its 60-day and 200-day moving averages. Despite some neutral signals from RSI and Stochastic Oscillator, the overall recommendation points towards a sell.
Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline
Deutsche Bank upgraded Qiagen N.V. (NYSE: QGEN) to Buy from Hold, maintaining a $54 price target, after the stock declined over 30% since late January. The firm notes that Qiagen’s 2026 outlook is back-end heavy, common for Diagnostics and Life Sciences companies, and is reasonably reflected in current consensus estimates. Despite macroeconomic challenges, Qiagen reiterated its 5% full-year growth estimate, anticipating improved growth in the second half due to new sample-preparation product introductions.
Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline
Deutsche Bank has upgraded Qiagen (QGEN) to Buy from Hold, maintaining a $54 price target, after the stock declined over 30% since late January. The firm believes the decline has priced out any buyout premium and noted that Qiagen's 2026 outlook, like many in its sector, is back-end heavy. Qiagen reiterated its 5% full-year growth estimate, anticipating improved growth in the second half due to new product introductions.
Qiagen N.V. Stock: Oversold Opportunity in Molecular Diagnostics Leader for North American Investors
Qiagen N.V. (NASDAQ:QGEN) shares are trading near 52-week lows, presenting a potential oversold opportunity for North American investors. Institutional investors like Allspring Global Investments have increased their stakes, and Deutsche Bank upgraded the stock to Buy, reflecting confidence in its molecular diagnostics leadership. The company's solid financial health, recurring revenue model, and strategic focus on genomics innovation position it for recovery and growth into 2026, despite broader biotech sector volatility.
Qiagen N.V. Stock: Leader in Molecular Diagnostics Faces CEO Transition Amid Steady Growth Outlook
Qiagen N.V. (ISIN: NL0012169213), a prominent molecular diagnostics leader, is undergoing a CEO transition while maintaining its 5% growth target for the year. North American investors are advised to monitor leadership changes, new product launches, and the company's strategic focus on innovation and sustainability. The company's resilience, diversified portfolio, and strong position in genomics tools make it an appealing option despite sector headwinds.
Bruker appoints QIAGEN CEO Thierry Bernard to board of directors
Bruker Corporation has appointed Thierry Bernard, the current CEO of QIAGEN N.V., to its board of directors, effective immediately. Bernard, who will step down from QIAGEN upon the appointment of his successor, brings extensive experience from his leadership roles at QIAGEN and bioMérieux SA. Frank Laukien, Bruker's CEO, stated that Bernard's expertise will aid the company's growth in life-science research, biopharma, and diagnostic solutions.
Qiagen N.V. Stock: Oversold Opportunity in Sample-to-Insight Leader Amid Biotech Sector Shifts
Qiagen N.V. shares are trading near 52-week lows, presenting a potentially oversold opportunity for North American investors interested in the molecular diagnostics and life sciences sector. The company, a leader in Sample-to-Insight solutions, has received analyst upgrades and seen increased institutional interest despite recent market pressure. Its strategic focus on high-growth areas like next-generation sequencing and precision medicine, coupled with its strong balance sheet, positions it for potential recovery and growth in the second half of 2026.
The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus Evidence - Learn Why
Qiagen (QGEN) recently released new clinical and health economic data for its QuantiFERON-TB Gold Plus blood test, showing improved tuberculosis detection and reduced healthcare costs. This strengthens the investment case by enhancing the product's clinical and economic credibility. While this supports Qiagen's long-term potential, the company's immediate focus remains on factors like QIAstat-Dx uptake and macroeconomic pressures affecting margins.
The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus Evidence - Learn Why
QIAGEN N.V. recently released new clinical and health economic data for its QuantiFERON-TB Gold Plus blood test, demonstrating improved tuberculosis detection and reduced lifetime healthcare costs compared to traditional methods. This evidence, supported by extensive studies, strengthens the test's role in preventive treatment and resource efficiency. The report suggests this expanded validation could impact Qiagen's investment narrative, particularly as the company pushes for increased adoption of its automated QIAstat-Dx systems amidst market competition.
QIAGEN NV Hits New 52-Week Low at USD 38.80 Amid Declining Performance
QIAGEN NV has fallen to a new 52-week low of USD 38.80, marking a 15.36% decline over the past year. Despite strong debt servicing capabilities and record operating cash flow, the company's long-term growth prospects are limited, with operating profit growing at only 5.15% annually over the last five years. The stock's current valuation indicates a complex landscape for investors.
Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection
Qiagen (QGEN) is under renewed focus following new clinical and health economic data supporting its QuantiFERON-TB Gold Plus test for tuberculosis detection, alongside an upcoming global online event. Despite recent share price momentum fading, the company's valuation narrative suggests it is 29.6% undervalued, with a fair value of $55.46 against a current trading price of $39.07. This outlook is supported by expected revenue growth, improved margins, and the launch of new high-throughput automation systems, though potential risks from weakening research budgets and regional pressures in China are noted.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM (the Netherlands Authority For the Financial Markets). The notification details a transaction on March 23, 2026, where BlackRock, Inc. adjusted its holdings in Qiagen N.V. The distribution overview shows BlackRock's total capital interest at 10.44% and voting rights at 11.59%, held indirectly through various subsidiaries.
Release according to Article 40, Section 1 of the WpHG
This article announces that BlackRock, Inc. has notified the AFM (the Netherlands Authority For the Financial Markets) of a significant change in its holdings and voting rights in QIAGEN N.V. The notification details the distribution of shares and voting rights by various BlackRock entities, categorizing them into real and potential holdings, and specifies the manner of disposal for some shares. Overall, BlackRock's total holding in QIAGEN N.V. is 10.44% and its total voting rights amount to 11.59%.
Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities
Qiagen N.V. (NYSE: QGEN) maintains a strong presence in molecular diagnostics and life sciences, offering critical technologies for sample preparation and assay development. The company serves diverse markets including diagnostics, applied testing, and research, benefiting from growth in areas like next-generation sequencing and human identification. With consistent financial performance and a balanced global footprint, Qiagen offers North American investors exposure to stable biotech tools though faces competitive and regulatory challenges.
Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities
Qiagen N.V. (QGEN) maintains a stable position in the molecular diagnostics and life sciences sector, providing essential sample and assay technologies for various applications. The company's diversified business model, global footprint, and focus on high-growth areas like next-generation sequencing and human identification make it an attractive consideration for North American investors seeking exposure to the biotech tools space. While facing competition and regulatory risks, Qiagen's consistent financial performance and strategic positioning suggest potential for gradual appreciation.
Qiagen (NYSE:QGEN) Sets New 52-Week Low - Time to Sell?
Qiagen (NYSE:QGEN) recently hit a new 52-week low of $38.89, trading below its 50-day and 200-day moving averages, indicating downward pressure. Despite mixed analyst sentiment (five Buys, seven Holds, one Sell) and an average price target of $55.20, the company did beat modest earnings estimates last quarter and has substantial institutional ownership. The article suggests investors consider whether the current low presents a selling opportunity or if the stock has potential for recovery given its fundamentals and analyst targets.
Qiagen N.V. Stock: A Core Player in Molecular Diagnostics for Long-Term Investor Focus
Qiagen N.V. (ISIN: NL0012169213) is highlighted as a leading molecular diagnostics and life sciences tools company, offering sample-to-insight solutions across genomics, diagnostics, and pharma research. The article details its business model, core operations emphasizing recurring revenue from consumables, and strong market position in areas like next-generation sequencing and point-of-care testing. It also addresses the company's relevance for North American investors, competitive advantages, and potential risks, positioning it as a key player for long-term focus.
Qiagen N.V. Stock: A Core Player in Molecular Diagnostics for Long-Term Investor Focus
Qiagen N.V. is presented as a key player in molecular diagnostics and life sciences tools, offering sample-to-insight solutions across genomics, diagnostics, and pharma research. The company's business model relies on a "razor-and-blade" approach with recurring consumable revenues and a strong global presence. North American investors are encouraged to consider Qiagen due to its significant U.S. revenue exposure, Nasdaq listing, dividend policy, and alignment with ESG factors.
QIAGEN NV Hits New 52-Week Low at USD 39.26 Amid Ongoing Decline
QIAGEN NV has reached a new 52-week low of USD 39.26, marking a 13.83% decrease in its stock over the past year. Despite strong financial health indicators like a low debt-to-equity ratio and high operating cash flow, the company has struggled with long-term growth and its stock performance has lagged behind the S&P 500. Its current valuation, however, appears discounted compared to peers.
Qiagen N.V. stock faces pressure amid biotech sector volatility and recent market caution
Qiagen N.V. stock has fallen 0.54% to EUR 35.33 on the Frankfurt exchange, reflecting broader volatility in the biotech sector. This dip, despite Qiagen's strong position in molecular diagnostics and genomics tools, indicates investor caution due to shifting demand dynamics and macroeconomic headwinds. US investors are advised to monitor this potential entry point, as the company's consumables-driven revenue model offers a degree of stability in an otherwise volatile market.
Should You Add QIAGEN Stock to Your Portfolio for Now?
The article discusses whether QIAGEN (QGEN) stock is a good addition to an investment portfolio. Unfortunately, the provided content is incomplete and lacks the detailed analysis necessary to make an informed decision.
Qiagen N.V. stock faces pressure amid biotech sector volatility and recent price dip on Frankfurt exchange
Qiagen N.V. (NL0012169213) stock recently dipped by 0.54% to EUR 35.33 on the Frankfurt exchange, reflecting broader pressures within the biotech sector. Despite this short-term selling pressure and market volatility, the company maintains a 'Starkes Signal' rating from analysts, suggesting underlying strength and potential for long-term upside. Key business drivers for Qiagen include its strong position in molecular diagnostics, offering recurring revenue from consumables for genomics and infectious disease testing, making it relevant for US investors seeking diversified life sciences exposure.
Should You Add QIAGEN Stock to Your Portfolio for Now?
NULL
JPMorgan Chase & Co. Has $33.09 Million Stake in Qiagen N.V. $QGEN
JPMorgan Chase & Co. significantly reduced its stake in Qiagen N.V. by 40.9% in the third quarter, now holding 740,649 shares valued at $33.09 million. Despite JPMorgan's reduction, other institutional investors like Vanguard and Amundi increased their positions, and several new stakes were initiated, leading to approximately 70% institutional ownership of Qiagen. Qiagen recently beat earnings estimates and has a consensus "Hold" rating with a target price of $55.20 from analysts.
Qiagen N.V. stock faces pressure amid genomics slowdown as DACH investors eye biotech resilience
Qiagen N.V. shares dipped after mixed Q4 2025 results revealed a 2% revenue decline and slower genomics demand. Despite maintaining its 2026 growth guidance, investors reacted to near-term softness in the genomics segment, though the diagnostics business showed resilience. DACH investors are closely monitoring the stock, given its significance in the European life sciences sector and the potential for recovery through renewed R&D funding and strategic expansions.
Agilent, Danaher could be potential buyers of Qiagen - analyst
This article mentions that an analyst views Agilent and Danaher as potential acquirers for Qiagen. No further details are provided in the current content.
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
QIAGEN N.V. announced it has filed its annual report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. Shareholders can access the document on the company's website or request printed copies free of charge. QIAGEN is a global leader in Sample to Insight solutions for Life Sciences and molecular diagnostics.
Qiagen N.V. stock rises on strong Q4 earnings and genomics demand surge amid AI biotech push
Qiagen N.V. reported stronger-than-expected Q4 results, with revenue beating estimates by 5% and adjusted EPS surpassing forecasts. The growth was driven by demand for genomic tools, particularly in AI-driven drug discovery and diagnostics, leading to a 4.2% intraday rise in its stock on the Frankfurt Stock Exchange. The company provided a positive 2026 guidance, expecting 7-9% revenue growth and increasing its dividend, highlighting its strong position in genomic innovation and relevance for DACH investors.
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
QIAGEN N.V. has filed its annual report on Form 20-F, including audited consolidated financial statements, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is accessible on QIAGEN's website, and shareholders can request printed copies free of charge. QIAGEN is a global leader in Sample to Insight solutions for life sciences and molecular diagnostics, employing approximately 5,700 people worldwide as of December 31, 2025.
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced the filing of its annual report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. Shareholders can access the document on QIAGEN's website and request printed copies free of charge. QIAGEN is a Netherlands-based global leader in Sample to Insight solutions for Life Sciences and molecular diagnostics.
PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act]
QIAGEN N.V. has filed its Form 20-F Annual Report for the fiscal year ended December 31, 2025, with the United States Securities and Exchange Commission (SEC). This announcement serves as a third-country release under Article 50 Para. 1, No. 2 of the German Securities Trading Act, ensuring Europe-wide distribution. The report is now accessible on QIAGEN's corporate website.
Qiagen N.V. stock gains spotlight with new QuantiFERON-TB data amid genomics challenges
Qiagen N.V. released new clinical data highlighting the efficacy of its QuantiFERON-TB Gold Plus test in reducing tuberculosis progression risk, especially in high-risk groups, counteracting pressure from a slowdown in genomics demand. Despite genomics headwinds impacting stock performance, the company's strong financial health and promising valuation metrics, along with continued innovation in diagnostics, present potential opportunities for investors, particularly in European markets. An upcoming World TB Day event will further showcase the test's applications and future developments.
Qiagen N.V. stock faces headwinds from genomics slowdown amid new TB test data
Qiagen N.V. is experiencing softening demand in its genomics consumables segment despite positive clinical trial data for its QuantiFERON-TB Gold Plus test. The company's razor-and-blade business model is under strain as labs reduce consumable usage, impacting recurring revenue visibility. However, strong performance in bioinformatic subscriptions and the promising TB diagnostic franchise offer a counterbalance, particularly for DACH investors who benefit from local operations and euro-denominated trading.
[IRANNOTICE] QIAGEN N.V. SEC Filing
QIAGEN N.V. has filed an IRANNOTICE with the U.S. Securities and Exchange Commission, disclosing information pursuant to the Iran Threat Reduction and Syria Human Rights Act and the Securities Exchange Act. This filing relates to disclosures made in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025. The notice, signed by CFO Roland Sackers, indicates that the company has adhered to these regulations regarding its activities.
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
QIAGEN announced new clinical and health economic data supporting its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, especially in immunocompromised and high-risk populations. A study showed QFT-Plus reduced the lifetime risk of active TB progression by 41% and lowered healthcare costs compared to tuberculin skin tests in HIV patients. The company will host a World TB Day event on March 24, 2026, to discuss advances in TB detection and prevention, while also developing a fifth-generation QuantiFERON and exploring AI for risk prediction.
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
QIAGEN announced new clinical and health economic data supporting the efficacy of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting TB infection, especially in immunocompromised and other high-risk populations. A recent study found QFT-Plus reduced the modeled lifetime risk of progressing to active TB by 41% compared to tuberculin skin testing, while also lowering healthcare costs. QIAGEN will host a World TB Day event on March 24, 2026, bringing together experts to discuss advancements in TB detection and prevention.
Qiagen’s TB And GI Testing Moves Draw Investor Valuation Interest
Qiagen (NYSE:QGEN) has released new clinical data supporting its QuantiFERON-TB Gold Plus test for tuberculosis, particularly for high-risk patients, and is planning a global TB awareness event. Additionally, the company received FDA clearance for its QIAstat-Dx Gastrointestinal Panels on the QIAstat-Dx Rise system for use in U.S. clinical laboratories. These developments highlight Qiagen's strategic positioning in infectious disease diagnostics and molecular lab automation, with shares currently trading below analyst targets and estimated fair value.
Qiagen N.V. Stock (ISIN: NL0012169213) Faces Headwinds Amid Genomics Slowdown and Strategic Shifts
Qiagen N.V. (ISIN: NL0012169213) is experiencing pressure due to a slowdown in demand for genomics consumables, a key revenue driver, as revealed in recent quarterly results. This has led to investor scrutiny over its growth prospects and valuation, particularly for European investors tracking Xetra-traded names. The company's "razor-and-blade" business model, while typically strong, is challenged by dipping pull-through rates, though its financial health remains solid amidst a competitive landscape.
Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays
Qiagen has partnered with South Korean company Gencurix to develop and commercialize digital PCR assays for cancer research and companion diagnostics. This collaboration aims to enhance Qiagen's portfolio in precision medicine for oncology, leveraging Gencurix's expertise in cancer diagnostics. The initial focus will be on the Korean market, with plans for global expansion.
Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays
Qiagen has partnered with South Korean molecular diagnostics firm Gencurix to develop and commercialize digital PCR assays for cancer research and treatment. The collaboration will initially focus on developing tests for new cancer biomarkers based on Gencurix's clinically validated oncology markers, which are used in its LiquidARRAY platform. This partnership aims to expand the range of available digital PCR solutions for oncology applications.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following a notification from the AFM on March 17, 2026. BlackRock, Inc. is identified as the person obliged to notify, with details provided on their direct and indirect holdings of QIAGEN N.V. shares and voting rights, totaling a capital interest of 10.33% and voting rights of 11.47%.
Moors & Cabot Inc. Acquires 154,851 Shares of Qiagen N.V. $QGEN
Moors & Cabot Inc. significantly increased its stake in Qiagen N.V. (NYSE:QGEN) by 78.2% in the third quarter, acquiring an additional 154,851 shares. This purchase brings their total holding to 352,809 shares, valued at approximately $15.76 million, making Qiagen their 29th largest position. Other major institutional investors also expanded their holdings, with institutional ownership now accounting for about 70% of Qiagen.
Qiagen N.V. Stock (ISIN: NL0012169213) Faces Pressure Amid Life Sciences Slowdown
Qiagen N.V. (NL0012169213) is experiencing pressure due to mixed quarterly results and cautious guidance in the diagnostics sector, particularly amidst a slowdown in life sciences R&D spending. While its core consumables business remains strong, the genomics segment faces headwinds from delayed research funding. European investors are closely monitoring the company's resilience, strategic diversification, and potential for recovery in precision medicine as management reaffirms full-year guidance.
Wellington Management Group LLP Lowers Stake in Qiagen N.V. $QGEN
Wellington Management Group LLP has reduced its stake in Qiagen N.V. ($QGEN) by 10.4% in the third quarter, selling over 2.6 million shares but still holding a significant portion of the company valued at over $1 billion. Despite the stock trading near its 12-month low, Qiagen recently exceeded EPS and revenue estimates. Analyst opinions are mixed, with a consensus "Hold" rating and an average price target of $55.20, although some firms have issued "Overweight" ratings.
Deutsche Bank upgrades Qiagen NV (QGEN)
Deutsche Bank has upgraded its rating for Qiagen NV (QGEN). This indicates a more positive outlook from the bank regarding the company's stock performance.
Qiagen N.V. $QGEN Position Raised by Perbak Capital Partners LLP
Perbak Capital Partners LLP significantly increased its stake in Qiagen N.V. (NYSE:QGEN) by 78.2% in the third quarter, making the stock its 13th-largest holding. Qiagen recently beat quarterly earnings and revenue estimates, showing a 3.6% year-over-year revenue increase. Despite a consensus "Hold" rating from analysts, some firms have issued "Buy" ratings with target prices ranging from $54.00 to $59.00.
